Pfizer starts work on new facility in Chesterfield, Mo.
The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work at multiple locations which the company leases in the St. Louis area.
Pfizer expects to hire an additional 80 employees over the coming years to support research at the site. Construction is expected to be complete by mid-2019.
The facility will provide approximately 295,000 square feet of R&D space to house Pfizer’s BioTherapeutics Pharmaceutical Sciences group and enabling partners.
This team is responsible for advancing Pfizer’s biologics, vaccines, and gene therapy portfolio by developing manufacturing processes and dosage forms applying state-of-the-art analytical technologies, conducting non-GMP manufacturing and scale-up studies.
This critical work enables the development of potential new medicines to treat ailments in oncology, rare disease, internal medicine, inflammation & immunology, and vaccines, including biosimilars. ■